Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy.
Yanlin FengXin NingJianlin WangZhaoyang WenFangfang CaoQing YouJianhua ZouXin ZhouTeng SunJimin CaoXiaoyuan ChenPublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Photoimmunotherapy, with spatiotemporal precision and noninvasive property, has provided a novel targeted therapeutic strategy for highly malignant triple-negative breast cancer (TNBC). However, their therapeutic effect is severely restricted by the insufficient generation of tumor antigens and the weak activation of immune response, which is caused by the limited tissue penetration of light and complex immunosuppressive microenvironment. To improve the outcomes, herein, mace-like plasmonic AuPd heterostructures (Au Pd HSs) have been fabricated to boost near-infrared (NIR) photoimmunotherapy. The plasmonic Au Pd HSs exhibit strong photothermal and photodynamic effects under NIR light irradiation, effectively triggering immunogenic cell death (ICD) to activate the immune response. Meanwhile, the spiky surface of Au Pd HSs can also stimulate the maturation of DCs to present these antigens, amplifying the immune response. Ultimately, combining with anti-programmed death-ligand 1 (α-PD-L1) will further reverse the immunosuppressive microenvironment and enhance the infiltration of cytotoxic T lymphocytes (CTLs), not only eradicating primary TNBC but also completely inhibiting mimetic metastatic TNBC. Overall, the current study opens a new path for the treatment of TNBC through immunotherapy by integrating nanotopology and plasmonic performance.
Keyphrases
- immune response
- sensitive detection
- reduced graphene oxide
- dendritic cells
- cell death
- visible light
- photodynamic therapy
- single molecule
- cancer therapy
- stem cells
- small cell lung cancer
- squamous cell carcinoma
- drug release
- toll like receptor
- energy transfer
- drug delivery
- room temperature
- signaling pathway
- radiation therapy
- type diabetes
- fluorescent probe
- weight loss
- combination therapy
- pi k akt